MedGenesis Therapeutix Inc.

MedGenesis Therapeutix (MedGenesis) is a privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diseases. MedGenesis is a worldwide leader in Convection Enhanced Delivery (CED), a minimally invasive technique that provides for targeted, local treatment of CNS conditions such as Parkinson’s disease, Epilepsy, Brain Cancer and other severely debilitating diseases of the CNS.

© MedGenesis Therapeutix Inc.

What's New

9-Oct-2012: MedGenesis Announces New Grant for the Development of GDNF

10-Jan-2012: MedGenesis Therapeutix raises $5.0 million in equity financing to support the Phase II development of GDNF in Parkinson's Disease